Simms v. Bayer Healthcare, LLC

by
The flea-and-tick “spot-on products” at issue claim that their active ingredient works by topical application to a pet’s skin rather than through the pet’s bloodstream. According to the manufacturers, after the product is applied to one area, it disperses over the rest of the pet’s body within one day because it collects in the oil glands and natural oils spread the product over the surface of the pet’s skin and “wick” the product over the hair. The plaintiffs alleged false advertising based on statements that the products are self-dispersing and cover the entire surface of the pet’s body when applied in a single spot; that they are effective for one month and require monthly applications to continue to work; that they do not enter the bloodstream; and that they are waterproof and effective after shampooing, swimming, and exposure to rain or sunlight. The district court repeatedly referred to a one-issue case: whether the product covers the pet’s entire body with a single application. The case management order stated that the manufacturers would bear the initial burden to produce studies that substantiated their claims; the plaintiffs would then have to refute the studies, “or these cases will be dismissed.” The manufacturers objected. The plaintiffs argued that the plan would save time, effort, and money. The manufacturers submitted studies. The plaintiffs’ response included information provided by one plaintiff and his adolescent son and an independent examination of whether translocation occurred that detected the product’s active ingredient in a dog’s bloodstream. The district court concluded that the manufacturers’ studies substantiated their claims and denied all of plaintiffs’ discovery requests, except a request for consumer complaints, then granted the manufacturers summary judgment. The Sixth Circuit affirmed. The doctrines of waiver and invited error precluded challenges to the case management plan. View "Simms v. Bayer Healthcare, LLC" on Justia Law